Cerevel Therapeutics Inc... (CERE)
44.96
0.33 (0.74%)
At close: Jul 31, 2024, 8:00 PM
0.74% (1D)
| Bid | n/a |
| Market Cap | 8.19B |
| Revenue (ttm) | 8.25M |
| Net Income (ttm) | -460.47M |
| EPS (ttm) | -2.73 |
| PE Ratio (ttm) | -16.468864468864467 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 15,033,754 |
| Avg. Volume (20D) | 2,056,487 |
| Open | 44.98 |
| Previous Close | 44.63 |
| Day's Range | 44.96 - 44.99 |
| 52-Week Range | 19.59 - 44.99 |
| Beta | 1.41 |
About CERE
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as we...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 30, 2020
Employees 355
Stock Exchange NASDAQ
Ticker Symbol CERE
Website https://www.cerevel.com
9 months ago
-2.26%
Cerevel Therapeutics shares are trading lower amid...
Unlock content with
Pro Subscription
